AETHERA is a randomized, double-blind, placebo controlled multicenter Phase III study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma (HL) following stem cell treatment (NCT01100502). The study recruited 329 patients aged 18 years or older with Hodgkin lymphoma who had received an autologous stem cell transplant (ASCT) in the previous 30-45 days, with adequate organ function. The trial evaluates the efficacy and safety of brentuximab vedotin, the best supportive care (BSC) compared to placebo, and the BSC in treatment of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT).
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Anna Sureda • 14 Jun 2017
Reinforcing transplantation with consolidation therapy in Hodgkin lymphoma
Anna Sureda • 26 Mar 2017